Quantum BioPharma clears FDA IND for PAD2-targeting MS drug Lucid-MS
Quantum BioPharma (NASDAQ: QNTM) has received FDA clearance of its Investigational New Drug application for Lucid-MS (Lucid-21-302), allowing the company to proceed into a randomised, double-blind, placebo-controlled Phase 2 trial in patients with multiple sclerosis. The clearance marks the first time a drug targeting the PAD2 enzyme has received regulatory authorisation to enter human testing in MS, a milestone the company frames as a potential turning point in an indication that has resisted meaningful functional recovery for decades.
The IND submission ran to approximately 15,000 pages, covering pharmacology, toxicology and manufacturing data. Lucid-MS completed Phase 1 studies in healthy volunteers, where the company says it showed an acceptable safety profile and was well tolerated. It now advances to the first controlled test in people living with progressive MS.
A different mechanism
Most approved MS therapies work by modulating or suppressing the immune system, a strategy that reduces relapse frequency but has limited impact on the progressive forms of the disease. Lucid-MS takes a distinct approach: it inhibits PAD2, an enzyme in the central nervous system that drives citrullination of myelin proteins, a chemical modification believed to directly trigger myelin breakdown. By targeting this process rather than immune function broadly, Quantum BioPharma is positioning the compound as potentially capable of halting and even reversing demyelination without incurring the infection risks associated with immunosuppressive regimens.
The compound is also being developed with oral dosing in mind, which, if confirmed in later trials, would offer a convenience advantage over injectable or infused alternatives. That said, preclinical animal-model results showing faster functional recovery and myelin preservation now face their first test in humans, and the field has a poor recent track record: remyelinating drug candidates from several larger companies have repeatedly produced mixed or negative outcomes in late-stage trials.
Alongside the drug programme, Quantum BioPharma is collaborating with scientists at Massachusetts General Hospital and Harvard Medical School on a PET imaging tracer, [¹⁸F]3F4AP, designed to visualise demyelination directly inside living patients. The team scanned its first MS patient in June 2025 using a combined PET-MR scanner, and peer-reviewed results were published two months later in the European Journal of Nuclear Medicine and Molecular Imaging. The work is NIH-funded and, if validated, could serve as a biomarker tool for any drug candidate targeting myelin, not only Lucid-MS.
Market and analyst context
The MS therapeutics market is large and competitive. Quantum cites analyst projections placing its global value at roughly $38.6 billion by 2030, though the company's own SEC filings are the primary source for that figure. The commercial landscape is dominated by established immunomodulatory products from companies including Biogen, Novartis and Roche, with several late-stage programmes also in progress. The progressive MS segment, which Lucid-MS is targeting, remains the least well-served: existing disease-modifying therapies offer limited benefit to patients with primary or secondary progressive disease, and no approved drug has demonstrated the ability to restore lost function.
Rodman and Renshaw initiated coverage of Quantum BioPharma with a Buy rating and an $8 price target following the IND clearance, describing Lucid-MS as a potentially first-in-class non-immunomodulatory small molecule. Kingswood Capital Partners issued unpaid coverage in September 2025 with a considerably higher $45 target, a figure built on a discounted cash flow model contingent on Phase 2 and Phase 3 success and a commercial launch by 2029. Investors should weigh those projections with caution given the speculative assumptions involved.
The Phase 2 readout will be the critical inflection point. Quantum has engaged a contract research organisation with CNS and MS experience for site selection, but no trial start date or enrolment target has been publicly disclosed. For a clinical-stage company with a genuinely novel mechanism, the next milestones to watch are protocol registration, site initiation, and the first interim safety and efficacy data.